Get the Stockscreener App
2.28
0.08%
-0.0019
After Hours:
2.66
0.38
+16.67%
Gt Biopharma Inc stock is traded at $2.28, with a volume of 10,903.
It is down -0.08% in the last 24 hours and down -3.39% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$2.2819
Open:
$2.3
24h Volume:
10,903
Relative Volume:
0.02
Market Cap:
$5.50M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.3293
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
+0.44%
1M Performance:
-3.39%
6M Performance:
-26.92%
1Y Performance:
-39.23%
1-Day Range:
$2.28
$2.32
1-Week Range:
$2.15
$2.38
52-Week Range:
$1.72
$10.66
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
315 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.255 | 398.00M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.99 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1685 | 343.35M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
JUNE
Dhandho Junoon Etf
|
10.76 | 215.97M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.64 | 126.17M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Nanobodies Market Growth, Opportunities and Future Scope 2025-2032 | Merck KGaA, Sanofi, AlpalifeB Inc - newstrail.com
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak - MSN
GT Biopharma Issues Warrant to Cytovance for Services Rendered - Investing.com Australia
GT Biopharma Issues Warrant to Cytovance for Services Rendered By Investing.com - Investing.com Canada
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Yahoo Finance
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
North American Morning Briefing : Stock Futures -2- - MarketScreener
GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Nanobodies Market Detailed In New Research Report 2025 | Sanofi, - openPR
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - MarketBeat
The Goodyear Tire & Rubber Company (GT): A Bull Case Theory - Yahoo Finance
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit - GlobeNewswire
Can GT Biopharma's TriKE® Technology Transform Blood Cancer Treatment? Phase 1 Trial Updates Coming in 2025 - StockTitan
GT Biopharma Launches Shareholder Communications Initiative - ACCESS Newswire
Roth Capital Has Weak Forecast for GT Biopharma Q1 Earnings - Defense World
Analysts Issue Forecasts for GT Biopharma FY2029 Earnings - Defense World
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial - ACCESS Newswire
GT Biopharma Announces $7.1 Million Convertible Debt Financing - ACCESS Newswire
GT Biopharma Announces Exercise of Warrants - GlobeNewswire
"Signal Advance, Inc. (OTC: SIGL) Achieves Technology - openPR
GT Biopharma announces warrant exercise, plans new offering - Investing.com India
GT Biopharma announces warrant exercise, plans new offering By Investing.com - Investing.com South Africa
GTBPGt Biopharma Inc Latest Stock News & Market Updates - StockTitan
Stock market today: Wah Fu Education Group +219.55%, Jet.AI +46.26% among top gainers in early trading - Business Upturn
Artificial Intelligence (AI) News Live Feed - StockTitan
GT Biopharma withdraws SEC registration statement - Investing.com India
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
GT Biopharma Pulls Back S-1 Filing: What Does This Mean for Their Financing Strategy? - StockTitan
GT Biopharma, Inc. SEC 10-K Report - TradingView
This New Nasdaq Biotech Could Revolutionize Emergency Cardiac CareHere's Why - StockTitan
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 5.1% - Defense World
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance
GT Biopharma Announces Recently Presented Data on Our Next Generation TriKE (OXS-C3550) at The Ash Meeting in Atlanta, GA - ACCESS Newswire
Nanobodies Market Analysis: Growth Drivers in Targeted - openPR
Pre-market Movers In Healthcare Sector: HUGE, ONTX, SVRA, CELC, CHFS... - RTTNews
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) - Defense World
Barnes Group (NYSE:B) Now Covered by StockNews.com - Defense World
Apollo Commercial Real Estate Finance (NYSE:ARI) Stock Rating Lowered by StockNews.com - Defense World
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):